Last reviewed · How we verify
NCT04098133: CPB-Epi Basel
Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital
trial testing data collection for demographic data in Infections With CPB in 100 participants. Currently enrolling.
30 June 2029
Quick facts
| Lead sponsor | University Hospital, Basel, Switzerland |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 22 August 2019 |
| Primary completion | 30 June 2029 |
| Estimated completion | 30 June 2029 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- data collection for demographic data
- data collection for clinical data
- data collection for treatment data
- data collection for microbiological data
Conditions studied
- Infections With CPB — all drugs for Infections With CPB →
Sponsor
University Hospital, Basel, Switzerland
Who can join
18 and older, any sex, with Infections With CPB. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.
Zingg S, Nicoletti GJ, Kuster S, Junker M, et al · · 2020 · cited 43× · PMID 32548207 · DOI 10.1093/ofid/ofaa185 -
Screening sites for detection of carbapenemase-producers- a retrospective cohort study.
Vock I, Ragozzino S, Urwyler P, Baumann M, et al · · 2024 · cited 2× · PMID 39741352 · DOI 10.1186/s13756-024-01513-2
Verify or expand the search:
- PubMed search for NCT04098133
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Basel, Switzerland trials
Trials by the same sponsor.
- NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
- NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
- NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
- NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
- NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04098133 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
- Last refreshed: 13 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04098133.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing